QB

QBiotics is an Australian life sciences company specializing in the discovery and development of small molecule pharmaceuticals derived from tropical rainforest plants. The company's lead compound, tigilanol tiglate (STELFONTA), is a novel diterpene ester that acts as a protein kinase C activator, inducing rapid tumor destruction through direct oncolysis and immune system stimulation. While STELFONTA is already commercially available for treating mast cell tumors in dogs, QBiotics is actively advancing a human clinical pipeline targeting various solid tumors and chronic wound healing. Their unique EcoLogic platform utilizes biodiscovery techniques to identify bioactive compounds from complex ecosystems, positioning the company as a leader in nature-derived drug development.